Contact:
Corporate Vice President, Communications & Investor Relations
T: +1 609 524 0065
E: mmp@genmab.com
For Investor Relations:
Senior Director, Investor Relations
T: +45 3377 9558
E: acn@genmab.com
(C) 2020 Electronic News Publishing, source
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,946 DKK | +0.46% | +0.65% | -9.81% |
06-04 | Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating | MT |
06-03 | Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study | MT |
Contact:
Corporate Vice President, Communications & Investor Relations
T: +1 609 524 0065
E: mmp@genmab.com
For Investor Relations:
Senior Director, Investor Relations
T: +45 3377 9558
E: acn@genmab.com
(C) 2020 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
-9.81% | 18.14B | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+4.60% | 22.67B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B | |
+86.61% | 9.32B |